PX-3

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
PX-3
APP-CHMINACA.svg
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C24H28N4O2
Molar mass 404.5 g/mol
3D model (JSmol)

PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication.[1][2][3]

The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, PX-1 (5F-APP-PICA, SRF-30), PX-2 (5F-APP-PINACA, FU-PX) and APP-FUBINACA were reported by the EMCDDA in late 2014.[4][5]

Legality[edit]

Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015.[6]

See also[edit]

References[edit]